NeoALTTO: European Journal of Cancer (EJC)

Title of Publication

Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer

AUTHORS

Paolo Nuciforo; John Townend; Martine J. Piccart; Shona Fielding; Panagiota Gkolfi, Sarra El-Abed; Evandro de Azambuja; Gustavo Werutsky; Judith Bliss; Volker Moebus; Marco Colleoni; Alvaro Moerno Aspitia; Henry Gomez; Andrea Gombos; Maria A. Coccia-Portugal; Ling-Ming Tseng; Georg Kunz; Guillermo Lerzo; Joohyuk Sohn; Vladimir Semiglazov; Cristina Saura; Judith Kroep; Antonella Ferro; David Cameron; Richard Gelber; Jens Huober; Serena Di Cosimo

Publication Reference

European Journal of Cancer (EJC) | Volume 181 | Issue | Page(s) 92-101 | Publication Year 2023

NordICC | The Lancet

May 5, 2026

Overview The Nordic-European Initiative on Colorectal Cancer (NordICC) study is a multinational, population-based randomized clinical trial set up to investigate the effectiveness of colonoscopy screening on colorectal cancer incidence and mortality in several...

APHINITY | Journal of the National Cancer Institute

Apr 17, 2026

Benefits of adjuvant pertuzumab and trastuzumab in subgroups of the APHINITY trial by HER2 FISH ratio and ER status.

FLAIR | British Journal of Haematology

Apr 1, 2026

Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib–rituximab versus fludarabine–cyclophosphamide–rituximab

COLONIZE | Annals of Internal Medicine

Nov 21, 2025

Fecal Microbiota Transplantation Versus Vancomycin for Primary Clostridioides difficile Infection

APHINITY | European Journal of Cancer

Jul 21, 2025

Body mass index and weight changes in patients with HER2-positive early
breast cancer: A sub-analysis of the APHINITY trial

ALEXANDRA | Journal of the American Medical Association (JAMA)

Feb 3, 2025

The addition of the immune therapy drug atezolizumab to chemotherapy after surgery did not provide benefit among patients with triple-negative breast cancer who are at high risk of recurrent disease.

ALTTO | ESMO Open

Oct 24, 2024

Final 10-year analysis of the ALTTO trial exploring dual anti-HER2 blockade with lapatinib + trastuzumab compared to trastuzumab alone.

APHINITY | Journal of Clinical Oncology

Sep 18, 2024

Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update

OlympiA results in the subset of patients from Japan

Apr 1, 2023

The consistency of results between the subset of patients from Japan and the global OlympiA population supports the clinical benefit of adjuvant olaparib for patients with gBRCA1/2pv and HER2-negative, high-risk eBC in Japan after completion of local treatment and neoadjuvant or adjuvant CT.